神经母细胞瘤
嵌合抗原受体
生物
癌症研究
抗原
细胞毒性T细胞
神经细胞粘附分子
免疫学
细胞培养
体外
免疫疗法
细胞
免疫系统
细胞粘附
遗传学
生物化学
作者
Denise L. Crossland,Warren L. Denning,Sonny Ang,Simon Olivares,Tiejuan Mi,Kirsten C. Switzer,Harjeet Singh,Helen M. Huls,Kate S. Gold,Bonnie S. Glisson,Laurence J.N. Cooper,John Victor Heymach
出处
期刊:Oncogene
[Springer Nature]
日期:2018-04-04
卷期号:37 (27): 3686-3697
被引量:72
标识
DOI:10.1038/s41388-018-0187-2
摘要
The CD56 antigen (NCAM-1) is highly expressed on several malignancies with neuronal or neuroendocrine differentiation, including small-cell lung cancer and neuroblastoma, tumor types for which new therapeutic options are needed. We hypothesized that CD56-specific chimeric antigen receptor (CAR) T cells could target and eliminate CD56-positive malignancies. Sleeping Beauty transposon-generated CD56R-CAR T cells exhibited αβT-cell receptors, released antitumor cytokines upon co-culture with CD56 + tumor targets, demonstrated a lack of fratricide, and expression of cytolytic function in the presence of CD56 + stimulation. The CD56R-CAR + T cells are capable of killing CD56 + neuroblastoma, glioma, and SCLC tumor cells in in vitro co-cultures and when tested against CD56 + human xenograft neuroblastoma models and SCLC models, CD56R-CAR + T cells were able to inhibit tumor growth in vivo. These results indicate that CD56-CARs merit further investigation as a potential treatment for CD56 + malignancies.
科研通智能强力驱动
Strongly Powered by AbleSci AI